Single User
£3750
PDF
40 pages

Gaucher’s Disease Forecast in 9 Major Markets 2015-2025


Gaucher’s Disease (GD) is caused by an inherited, autosomal recessive mutation in the GBA gene. This gene is responsible for providing the instructions for the production of the enzyme glucocerebrosidase. Without this enzyme, glucocerebroside and other similar substances can accumulate in macrophages and monocytes (white blood cells) and are deposited in various organs, including the spleen, liver, kidneys and lungs. This build-up can reach toxic levels which results in organ and tissue damage. This report provides the current prevalent population for GD across 9 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil, Japan and India) split by gender and 5-year age cohort. Along with the current prevalence, the report provides an overview of the types, occlusion locations and the prevalence of associated disorders of GD. The report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of GD have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for GD include:

  • Splenomegally
  • Hepatomegally
  • Haematological conditions
  • Musculoskeletal conditions
  • Gall stones

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to Purchase:

  • Able to quantify patient populations in global GD’s market to target the development of future products, pricing strategies and launch plans.
  • Gain further insight into the prevalence of the subdivided types of GD and identify patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Provide a level of understanding on the impact from specific co-morbid conditions on GD’s prevalent population.
  • Examination of the prevalence of the different causative gene mutations for GD.
  • Identify sub-populations within GD which require treatment.
  • Gain an understanding of the specific markets that have the largest number of GD patients.

Table of Contents

  • List of Tables and Figures
  • Introduction
  • Cause of the Disease
  • Risk Factors and Prevention
  • Diagnosis of the Disease
  • Variation by Geography /Ethnicity
  • Disease Prognosis and Clinical Course
  • Key Co-Morbid Conditions / Features Associated with the Disease
  • Methodology for Quantifications of Patient Number
  • Top Line Prevalence for Gaucher’s Disease (GD)
  • Main Complications and Features of GD
    • Phenotypic Sub-type of GD Patients
    • Genotype of Type I GD Patients
    • Genotype of Type III GD Patients
    • Musculoskeletal Complications of GD
    • Haematological Involvement of GD
  • References
  • Appendix

List of Tables and Figures

  • Prevalence of GD, total (000s)
  • Prevalence of GD, males (000s)
  • Prevalence of GD, females (000s)
  • GD by Phenotypic sub-Type, total (000s)
  • Genotype of Type I GD Patients, total (000s)
  • Genotype of Type III GD Patients, total (000s)
  • Bone and Joint Pain in Patients with GD, total (000s)
  • Radiological Bone Disease in Patients with GD, total (000s)
  • Erlenmeyer Flask Deformity in Patients with Type I GD, total (000s)
  • Presence of Anaemia in Patients with GD, total (000s)
  • Presence of Thrombocytopenia in Patients with GD, total (000s)
  • Presence of Bleeding Tendencies in Patients with GD, total (000s)
  • USA Prevalence of GD by 5-yr age cohort, males (000s)
  • USA Prevalence of GD by 5-yr age cohort, females (000s)
  • France Prevalence of GD by 5-yr age cohort, males (000s)
  • France Prevalence of GD by 5-yr age cohort, females (000s)
  • Germany Prevalence of GD by 5-yr age cohort, males (000s)
  • Germany Prevalence of GD by 5-yr age cohort, females (000s)
  • Italy Prevalence of GD by 5-yr age cohort, males (000s)
  • Italy Prevalence of GD by 5-yr age cohort, females (000s)
  • Spain Prevalence of GD by 5-yr age cohort, males (000s)
  • Spain Prevalence of GD by 5-yr age cohort, females (000s)
  • United Kingdom Prevalence of GD by 5-yr age cohort, males (000s)
  • United Kingdom Prevalence of GD by 5-yr age cohort, females (000s)
  • Brazil Prevalence of GD by 5-yr age cohort, males (000s)
  • Brazil Prevalence of GD by 5-yr age cohort, females (000s)
  • Japan Prevalence of GD by 5-yr age cohort, males (000s)
  • Japan Prevalence of GD by 5-yr age cohort, females (000s)
  • India Prevalence of GD by 5-yr age cohort, males (000s)
  • India Prevalence of GD by 5-yr age cohort, females (000s)
Brazil, France, Germany, India, Italy, Japan, Spain, United Kingdom, United States of America